prefilled leuprolide syringe with no mixing required1
Discover Camcevi®
*CAMCEVI was evaluated in an open-label, single arm, multinational study involving 137 patients with advanced prostate cancer with a baseline morning serum testosterone level of >150 ng/dL and ECOG performance status of ≤2. CAMCEVI was dosed subcutaneously, 42 mg on Day 0 and again at Week 24.1
The primary endpoint was medical castration rate, defined as achieving and maintaining serum testosterone suppression to ≤50 ng/dL by Week 4 through Week 48 of treatment after the initial injection.1